WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics

Reuters

2025/07/16

WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics

WuXi Biologics (Cayman) Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on July 16, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2551141730"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2551141730\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2551141730?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 17:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2551141730","market":"nz","top_or_hot":-1,"title":"WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi Biologics (Cayman) Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. published the original content used to generate this news brief on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-16 17:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        WuXi Biologics (Cayman) Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/WXIBF\">Wuxi Biologics (Cayman) Inc</a>. published the original content used to generate this news brief on July 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nNDL81NBGJ:1","article_id":"2551141730","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2551141730","pubTimestamp":1752659320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"WuXi Biologics  Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should n","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物","MSCI":"MSCI Inc"},"translate_title":"药明生物获得晨星Sustainalytics的可忽略风险ESG评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSCI":0.9,"02269":0.9},"content_text":"WuXi Biologics Achieves Negligible-Risk ESG Rating from Morningstar Sustainalytics\n    \n\n        WuXi Biologics (Cayman) Inc. has announced that it has received the highest negligible-risk ESG rating from Morningstar Sustainalytics. This rating places the company in the top 1% globally, according to the 2025 ESG Risk Ratings conducted by the firm. This marks the fifth consecutive year that WuXi Biologics has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics. The company is a participant in the United Nations Global Compact and the Pharmaceutical Supply Chain Initiative, indicating its ongoing commitment to sustainability. WuXi Biologics has also received several other recognitions, including an MSCI AAA rating, an EcoVadis Platinum Medal, and inclusion in the Dow Jones Sustainability Indices, among others.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief on July 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}